Investigating KRAS-G12C inhibitors: How might they improve outcomes for patients with solid tumours?
touchTALKS for touchONCOLOGY
Listen to an esteemed lung cancer expert discuss KRAS mutations in solid tumours, particularly non-small cell lung cancer and colorectal cancer, and consider the role of direct KRAS-G12C inhibitors in targeting these mutations and potential strategies to overcome resistance.
- Prof. Tony Mok, Chinese University of Hong Kong, Hong Kong
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Novartis. This activity is provided by touchIME.
For further information visit our website: https://touchoncology.com/education/kras-g12c-inhibitors-for-solid-tumours/